This is a randomized, placebo controlled; parallel study that will be conducted on 66 female
patients with advanced epithelial ovarian carcinoma (stage III and stage IV) to compare
effect of adding Itraconazole to paclitaxel and carboplatin versus placebo to paclitaxel and
carboplatin as regard overall response rate (ORR) and Disease control rate (DCR) and Quality
of life (QOL) and the change in the serum concentrations of the biological markers.